Full-Time

Senior Research Associate

Chemical Biology

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$95k - $120kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree or Master’s degree in molecular biology, biochemistry, biotechnology, or related field
  • 5+ years of experience in a cell biology/molecular biology role
  • Hands-on experience culturing, manipulating and characterizing mammalian cells: cell culture, viability and other bioassays (e.g. western blot, qPCR, CTG)
  • Experience with biochemical and recombinant protein assays and protein analysis by LC-MS
  • Excellent written and verbal communication, attention to detail, and record keeping
  • An energetic and proactive team player with the ability to work efficiently in a dynamic company environment
Responsibilities
  • Work with scientists in the Chemical Biology and Proteomics team to follow up on biochemical and cellular high-throughput screening hits and perform mechanistic experiments as part of hit validation efforts
  • Perform bioassays to interrogate effects of novel compounds on cellular pathways, including plate-based cellular assays using reagent kits and automated liquid handlers
  • Engineer cell lines and establish cellular assay systems
  • Maintain cultures of multiple cancer cell lines to support experimental efforts
  • Generate high quality data in a timely manner and maintain detailed experimental records
  • Work with project scientists to process and analyze data and design new experiments
  • Regularly and effectively communicate findings at group meetings

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?